Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCN: Letrozole plus chemotherapy in HR+ breast cancer
NCT02769104Phase 3Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2016
- Primary completion
- Jul 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of letrozole in breast cancer, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Effective rate at 6 months. Status: unknown.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02769104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02769104.